New drug cocktail aims to shrink head and neck tumors before surgery
NCT ID NCT05977907
First seen Mar 14, 2026 · Last updated Jun 19, 2026 · Updated 13 times
Summary
This phase 2 trial is testing whether giving two drugs—pembrolizumab (Keytruda) and IO102-103—before surgery is safe and effective for people with head and neck cancer. The study will enroll 30 adults whose cancer can be surgically removed. Researchers will watch for side effects and check if the drugs shrink tumors by at least 50% before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern Memorial Hospital
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
Contact
-
Providence Cancer Institute
NOT_YET_RECRUITINGPortland, Oregon, 97213, United States
Contact
-
Sibley Memorial Hospital
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20016, United States
Contact
-
Thomas Jefferson University Hospital
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) and IO102-103
What this could lead to
If successful, this could point toward a new pre-surgery treatment that shrinks head and neck cancers, potentially improving surgical outcomes.
What could go wrong
This is a small, early-phase trial with only 30 participants. The drugs may cause side effects or delay surgery, and it's unknown if they will work better than current treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.